Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization.

Cytokine

PubMedID: 26163999

Kim SS, Cho HJ, Won JH, Bae JI, Kang DR, Lee JD, Shin SJ, Lee KM, Yoo BM, Kim JK, Lee JH, Ahn SJ, Park JH, Cho SW, Cheong JY. Interleukin-8 level as a prognostic marker in patients with hepatitis B virus-associated hepatocellular carcinoma treated with transarterial chemoembolization. Cytokine. 2015;.
We investigated the association between serum interleukin (IL)-8 levels and post-transarterial chemoembolization (TACE) outcomes in patients with hepatitis B virus (HBV)-associated HCC. We enrolled 119 TACE-treated patients with HBV-associated HCC; TACE refractoriness and liver transplantation (LT)-free survival were evaluated during follow-up. Pre-TACE serum levels of various cytokines (epidermal growth factor [EGF], fibroblast growth factor 2, granulocyte-colony stimulating factor [G-CSF], interferon-?, IL-8, IL-12, IL-17A, interferon-?-inducible protein-10, monocyte chemotactic protein-1, tumor necrosis factor-a and vascular endothelial growth factor) were analyzed. During a mean follow-up of 24. 3 (1-79) months, 91 patients (76. 5%) exhibited TACE refractoriness. In multivariate analyses, multiple tumors (hazard ratio [HR], 2. 37; 95% confidence interval [CI], 1. 28-4. 39; P=0. 006), large tumor size (HR, 2. 36; 95% CI, 1. 38-4. 03; P=0. 002), and combination of alpha-fetoprotein and IL-8 levels (AFP>400ng/mL or IL-8>32pg/mL; HR, 1. 72; 95% CI, 1. 03-2. 85; P=0. 037) independently predicted overall TACE refractoriness. Higher EGF (>35pg/mL) and lower G-CSF levels (?12. 5pg/mL) were associated with early TACE refractoriness (<1year; HR, 3. 47; 95% CI, 1. 01-11. 96; P=0. 049 and HR, 6. 25; 95% CI, 1. 62-23. 81; P=0. 008, respectively). Furthermore, high IL-8 level (>32pg/mL; HR, 1. 68; 95% CI, 1. 09-2. 59; P=0. 020) was associated with poor LT-free survival. In conclusion, pretreatment serum IL-8 is a useful prognostic marker for TACE refractoriness and LT-free survival in TACE-treated patients with HBV-associated HCC.